Alsu Faskhieva/iStock via Getty Images
Shares of Forte Biosciences (FBRX) climbed on Thursday after the company posted early-stage trial results indicating that its lead asset, FB102, led to a statistically significant improvement in vitiligo symptoms as early as nine weeks.
The primary endpoint of the
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。